CD19 and diffuse large B-cell lymphoma: As well, KTE-C19 as an autologous CD3ζ/CD28-based CD19-specific CAR-T cell product at a target dose of 2 × 106 CAR-T cells/kg showed an acceptable safety profile along with an overall response rate of about 71%, and a complete response rate of about 57% in a participant with refractory DLBCL [56].